EyePoint, Inc. EYPT R2K

Healthcare · Biotechnology · United States

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Market & Price

Market Cap

$1.14B

Current Price

$13.58

High / Low (52W)

$18.85 / $7.24

Beta

1.77

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.40

Price to Book

34.29

P/S

149.54

EV/EBITDA

-4.52

Dividend Yield

Profitability & Returns

ROCE

-70.85%

ROE

-102.71%

ROA

-54.13%

Profit Margin

0.00%

Op Margin

EPS (Latest Qtr)

$-0.99

EPS (TTM)

$-3.51

Balance Sheet & Liquidity

Debt/Equity

0.47

Quick Ratio

5.97

Current Ratio

6.66

Debt

$17.62M

Total Assets

$364.00M

Current Assets

$328.65M

Working Capital

$291.63M

Ownership

Promoter Holding

3.68%

Chg in Prom Hold

FII / Inst Holding

110.05%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.26B

Total Revenue (TTM)

$7.61M

EBITDA

$-279.38M

Free Cash Flow

$-168.72M

Operating Cash Flow

$-267.54M

Shares Outstanding

83.84M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-8.83%

Profit 5Y

-42.28%

Revenue (YoY)

161.70%

Earnings (YoY)

PROS

No notable strengths flagged.

CONS

Revenue declined at -8.8% CAGR over 5 years.
Earnings shrank at -42.3% CAGR over 5 years.
Trading 28.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	EYPT EyePoint, Inc. R2K	13.58	-	$1.14B	-	-70.85%	-102.71%	-8.83%	-42.28%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	277.00K	5.97M	590.00K	701.00K	385.00K	933.00K	928.00K	715.00K	486.00K	2.44M	2.01M	7.21M	2.51M	8.63M	7.49M	4.12M	15.70M	7.32M	9.01M	9.06M	9.29M	11.56M	10.01M	7.68M	9.11M	15.20M	11.68M	9.48M	-	-	24.45M	5.33M	966.00K	620.00K	696.00K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	805.00K	165.00K	721.00K	375.00K	528.00K
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.65M	5.17M	245.00K	245.00K	168.00K
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72.48M	67.39M	62.27M	70.59M	87.39M
Operating Income	-5.20M	-4.98M	-5.24M	-5.10M	-6.46M	-7.19M	-94.00K	-5.16M	-6.14M	-6.01M	-5.81M	-4.68M	-9.78M	-13.55M	-11.01M	-14.65M	-10.16M	-14.06M	-8.98M	-11.44M	-11.15M	-1.96M	-10.94M	-10.98M	-15.31M	-18.28M	-19.22M	-18.40M	-21.55M	-22.76M	-14.40M	-33.32M	-34.55M	-	-	-48.84M	-62.23M	-62.02M	-70.34M	-87.23M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-48.34M	-61.69M	-61.45M	-57.86M	-86.59M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	14.00K	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-45.20M	-59.33M	-59.73M	-67.42M	-84.88M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	93.00K	0	186.00K	-50.00K
Net Income	-5.15M	-4.93M	-5.19M	-5.04M	-6.39M	-7.16M	-67.00K	-5.14M	-6.12M	-5.98M	-5.78M	-6.98M	-34.43M	-33.13M	-11.59M	-19.24M	-11.50M	-15.65M	-10.41M	-13.17M	-12.95M	-3.80M	-12.28M	-10.01M	-16.70M	-20.98M	-19.41M	-18.42M	-21.16M	-22.92M	-12.61M	-29.28M	-30.83M	-	-	-45.20M	-59.43M	-59.73M	-67.61M	-84.83M
Diluted EPS	-0.17	-0.17	-0.18	-0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.35	-0.58	-0.56	-0.52	-0.49	-0.56	-0.61	-0.33	-0.55	-0.58	-	-	-0.65	-0.85	-0.85	-0.81	-0.99
R&D Expense	-	3.48M	3.72M	3.07M	-	4.18M	3.17M	3.32M	-	3.82M	4.27M	3.33M	4.76M	6.23M	-	3.80M	3.96M	3.48M	-	4.85M	3.28M	4.09M	5.48M	5.61M	8.50M	9.95M	12.99M	11.16M	13.62M	15.73M	17.36M	30.14M	29.82M	29.54M	-	58.57M	55.50M	47.75M	-	72.15M

Profit & Loss (Annual)

Figures in USD.

Metric	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	1.62M	7.54M	2.96M	4.57M	20.36M	34.44M	-	41.40M	46.02M	43.27M	31.37M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	8.33M	4.63M	3.71M	2.07M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	33.08M	41.39M	39.56M	29.30M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	112.02M	116.45M	185.41M	272.74M
Operating Income	9.09M	-10.00M	-25.21M	-12.03M	-13.49M	6.42M	-21.77M	-18.58M	-26.27M	-39.02M	-47.86M	-37.29M	-	-78.94M	-75.07M	-145.85M	-243.43M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-96.62M	-69.00M	-129.23M	-229.34M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	3.19M	1.25M	14.00K	33.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-102.25M	-70.71M	-130.78M	-231.68M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	0	83.00K	90.00K	279.00K
Net Income	8.75M	-8.63M	-24.84M	-11.90M	-13.36M	6.35M	-21.55M	-18.48M	-53.17M	-86.12M	-56.79M	-45.39M	-	-102.25M	-70.80M	-130.87M	-231.96M
Diluted EPS	0.46	-0.44	-1.19	-0.52	-0.49	0.21	-0.68	-0.52	-	-	-	-	-	-2.74	-1.82	-2.32	-3.17
R&D Expense	6.99M	6.86M	7.04M	7.00M	9.57M	12.09M	14.38M	14.88M	16.18M	18.50M	15.37M	17.42M	28.50M	49.64M	64.66M	132.93M	221.04M

Compounded Sales Growth

5 Years:	-8.83%
1 Year:	161.70%

Compounded Profit Growth

5 Years:	-42.28%
1 Year:	-

Stock Price Performance

1 Year:	+87.57%
6 Months:	-7.87%
3 Months:	-22.67%
1 Month:	+5.60%

Balance Sheet (Annual)

Figures in USD.

Metric	Jun 2009	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	47.11M	20.60M	16.25M	22.67M	32.37M	31.62M	18.68M	71.67M	78.17M	72.97M	91.72M	-	180.36M	355.18M	418.46M	364.00M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	172.81M	344.80M	383.31M	328.65M
Cash & Equivalents	6.90M	15.51M	12.91M	4.62M	6.90M	15.33M	19.12M	15.31M	16.90M	38.78M	45.26M	22.21M	44.91M	-	95.63M	281.26M	99.70M	101.82M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.89M	3.91M	2.31M	1.81M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.50M	805.00K	607.00K	651.00K
Total Liabilities	-	-	9.68M	6.96M	8.55M	7.75M	9.00M	10.74M	5.34M	59.98M	40.53M	64.64M	73.18M	-	83.99M	88.86M	81.96M	57.88M
Current Liabilities	-	-	5.03M	3.18M	3.30M	2.13M	3.35M	5.09M	5.29M	21.66M	21.46M	11.52M	14.89M	-	34.54M	63.26M	49.05M	37.02M
Long Term Debt	-	-	-	-	-	-	-	-	0	17.31M	17.62M	47.22M	37.98M	36.56M	29.31M	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45.77M	4.91M	21.86M	20.77M
Total Equity	23.54M	33.04M	37.43M	13.64M	7.70M	14.92M	23.37M	20.88M	13.34M	11.69M	37.63M	8.33M	18.54M	-	96.37M	266.32M	336.50M	306.11M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34.08M	49.04M	68.27M	82.83M

Cash Flows (Annual)

Figures in USD.

Metric	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	9.90M	-3.17M	-9.00M	-8.74M	-	-	-16.32M	-20.49M	-21.91M	-56.70M	-14.44M	-	-65.00M	1.88M	-126.23M	-240.11M
Investing Cash Flow	-2.07M	-9.50M	606.00K	6.36M	-	-	-4.46M	13.58M	-16.89M	-213.00K	-362.00K	-	-17.27M	-3.31M	-219.35M	68.58M
Financing Cash Flow	802.00K	10.06M	114.00K	4.67M	-	-	16.99M	8.50M	60.67M	33.86M	37.49M	-	-690.00K	187.07M	164.02M	173.65M
Capital Expenditure	-15.00K	-133.00K	-405.00K	-68.00K	-248.00K	-161.00K	-113.00K	-147.00K	-108.00K	-213.00K	-362.00K	-	-2.15M	-3.48M	-4.05M	-3.28M
Free Cash Flow	9.88M	-3.30M	-9.41M	-8.81M	-	-	-16.43M	-20.64M	-22.02M	-56.91M	-14.80M	-	-67.16M	-1.61M	-130.28M	-243.39M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-82.96M	185.63M	-181.56M	2.12M

Ratios (Annual)

Figures in %.

Metric	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	79.9%	89.9%	91.4%	93.4%
Operating Margin %	-	-	-	-	-	-	-1,344.1%	-246.4%	-887.3%	-853.6%	-235.0%	-108.3%	-	-190.7%	-163.1%	-337.1%	-776.0%
Net Margin %	-	-	-	-	-	-	-1,330.1%	-245.2%	-1,795.7%	-1,884.2%	-278.9%	-131.8%	-	-247.0%	-153.8%	-302.4%	-739.4%
ROE %	26.5%	-23.0%	-182.1%	-154.5%	-89.5%	27.2%	-103.2%	-138.6%	-455.0%	-228.9%	-681.8%	-244.8%	-	-106.1%	-26.6%	-38.9%	-75.8%
ROCE %	-	-23.8%	-144.7%	-92.9%	-65.7%	22.1%	-82.1%	-138.8%	-52.5%	-68.8%	-77.9%	-48.5%	-	-54.1%	-25.7%	-39.5%	-74.5%

Shareholding Pattern

Insiders

3.68%

Institutions

110.05%

Public Float

114.25%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Suvretta Capital Management, LLC	9.90%	8.30M	$112.66M
2	Cormorant Asset Management, LP	9.86%	8.27M	$112.24M
3	Blackrock Inc.	8.56%	7.18M	$97.47M
4	Federated Hermes, Inc.	6.76%	5.67M	$76.99M
5	Franklin Resources, Inc.	6.02%	5.05M	$68.56M
6	Janus Henderson Group PLC	4.30%	3.60M	$48.90M
7	Vanguard Capital Management LLC	4.25%	3.56M	$48.34M
8	Adage Capital Partners GP L.L.C.	3.94%	3.30M	$44.81M
9	Paradigm Biocapital Advisors LP	3.75%	3.14M	$42.67M
10	Commodore Capital Lp	3.37%	2.83M	$38.36M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EYPT

No recent headlines available.

EYPT · Healthcare

EyePoint, Inc.

About

Key Facts

Sector	Healthcare
Industry	Biotechnology
Headquarters	United States
Employees	214
Website	https://eyepoint.bio

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

EyePoint, Inc. EYPT R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More